All In Biotech

Free tool

FAERS Monitor: Empliciti

The FDA Adverse Event Reporting System collects reports from patients, clinicians and manufacturers. Counts are unverified reports, not rates: they rise with how widely a drug is used, how long it has been sold and media attention, a report can name several drugs, and a report does not show the drug caused the event.

Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations

Reports naming BLA 761035 or its brand name (Empliciti, Elotuzumab). Reports on generic versions are filed under their own applications.

Reports

5,171

Serious

4,210

81% of reports

Hospitalization

2,018

Death reported

920

Any cause; not necessarily from the drug

Most reported reactions

MedDRA preferred terms.

  • plasma cell myeloma576
  • pneumonia304
  • death298
  • malignant neoplasm progression254
  • fatigue236
  • diarrhoea231
  • pyrexia221
  • drug ineffective204
  • neutropenia194
  • anaemia173
  • thrombocytopenia146
  • off label use142
  • platelet count decreased134
  • sepsis124
  • neuropathy peripheral115

Reports by year received

View as table
YearReports
20102
20118
201241
2013110
2014102
2015120
2016495
2017691
2018598
2019622
2020629
2021566
2022392
2023283
2024190
2025207
2026115

Disproportionality screen

Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,988 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.

ReactionReportsPRR95% CI lowerChi-squared
plasma cell myelomaSignal57660.956.433,457
malignant neoplasm progressionSignal25410.19.02,081
neutropeniaSignal1945.85.1772
thrombocytopeniaSignal1465.34.5509
platelet count decreasedSignal1345.14.3442
neuropathy peripheralSignal1154.94.1357
sepsisSignal1244.53.8338
pneumoniaSignal3043.83.4640
anaemiaSignal1733.73.2340
pyrexiaSignal2212.62.3219
diarrhoea2311.51.334
death2981.41.336
fatigue2361.21.111
off label use1420.70.626
drug ineffective2040.60.647

A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.